<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05012618</url>
  </required_header>
  <id_info>
    <org_study_id>LUN101JG</org_study_id>
    <nct_id>NCT05012618</nct_id>
  </id_info>
  <brief_title>A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).</brief_title>
  <official_title>A Phase 1 Open-label, Dose-escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 dose-escalation and cohort expansion study that will evaluate the safety,&#xD;
      pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of LUNA18 in patients&#xD;
      with locally advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of LUNA18 (Dose-limiting toxicities) [Part A]</measure>
    <time_frame>From Cycle 0 Day 1 until Cycle 1 Day 28 (Cycle 0 is 6-9 days, and Cycle 1 is 28 days)</time_frame>
    <description>Incidence and nature of dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of LUNA18 (Adverse Events) [Part A, B and C]</measure>
    <time_frame>From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)</time_frame>
    <description>Incidence, nature and severity of adverse events, with severity determined per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of LUNA18 [Part A]</measure>
    <time_frame>From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)</time_frame>
    <description>Plasma concentrations of LUNA18</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of LUNA18 [Part A]</measure>
    <time_frame>From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)</time_frame>
    <description>Maximum plasma concentration (Cmax) of LUNA18</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma drug concentration (Tmax) of LUNA18 [Part A]</measure>
    <time_frame>From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)</time_frame>
    <description>Time to reach maximum plasma drug concentration (Tmax) of LUNA18</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration versus time curve (AUC) of LUNA18 [Part A]</measure>
    <time_frame>From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)</time_frame>
    <description>Area under the concentration versus time curve (AUC) of LUNA18</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phosphorylation level of ERK protein (pERK) in tumor tissues [Part B]</measure>
    <time_frame>From screening until the time of clinical responses and/or the time of progressive disease (up to approximately 43 months), if feasible</time_frame>
    <description>Phosphorylation level of ERK protein (pERK) in tumor tissues biomarkers as applicable in tumor tissues</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preliminary anti-tumor activity of LUNA18 [Part C]</measure>
    <time_frame>From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)</time_frame>
    <description>Objective response, defined as a confirmed complete response (CR) or partial response (PR) as best overall response per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity of LUNA18 [Part A]</measure>
    <time_frame>From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)</time_frame>
    <description>Objective response, defined as CR or PR as best overall response per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity of LUNA18 [Part A, B and C]</measure>
    <time_frame>From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)</time_frame>
    <description>Disease control, defined as CR, PR and stable disease (SD) per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity of LUNA18 [Part A, B and C]</measure>
    <time_frame>From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)</time_frame>
    <description>Duration of response (DoR), defined as the time from the first occurrence of a documented objective response to the time of the first documented disease progression per RECIST v1.1 or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity of LUNA18 [Part A, B and C]</measure>
    <time_frame>From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)</time_frame>
    <description>Progression free survival (PFS), defined as the time from the first study treatment to the first occurrence of progression per RECIST v1.1 or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody to LUNA18 [Part A, B and C]</measure>
    <time_frame>From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)</time_frame>
    <description>Incidence of anti-LUNA18 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of LUNA18 [Part B and C]</measure>
    <time_frame>From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)</time_frame>
    <description>Plasma concentrations of LUNA18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphorylation level of ERK protein (pERK) in tumor tissues [Part A and C]</measure>
    <time_frame>From screening until the time of clinical responses and/or the time of progressive disease (up to approximately 43 months), if feasible</time_frame>
    <description>Phosphorylation level of ERK protein (pERK) in tumor tissues biomarkers as applicable in tumor tissues</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Locally Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose escalation part (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive LUNA18 capsule(s) at escalated doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker part (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive LUNA18 capsule(s) at doses where the tolerability is confirmed in Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort expansion part (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive LUNA18 capsule(s) at the recommended dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LUNA18</intervention_name>
    <description>LUNA18 Capsule</description>
    <arm_group_label>Biomarker part (Part B)</arm_group_label>
    <arm_group_label>Cohort expansion part (Part C)</arm_group_label>
    <arm_group_label>Dose escalation part (Part A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years at time of signing informed consent form&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Patients with a histologically or cytologically proven diagnosis of a locally&#xD;
             advanced, recurrent, or metastatic incurable solid tumor for which standard therapy&#xD;
             either does not exist or has proven ineffective or intolerable&#xD;
&#xD;
          -  Patients with documented RAS alterations positive solid tumors&#xD;
&#xD;
          -  Patients with measurable disease per RECIST v1.1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac&#xD;
             disease (Class II or greater), unstable angina, or myocardial infarction within the&#xD;
             previous 6 months or unstable arrhythmias within the previous 3 months&#xD;
&#xD;
          -  Patients with primary central nervous system (CNS) malignancy, untreated CNS&#xD;
             metastases requiring any anti-tumor treatment, or active CNS metastases&#xD;
&#xD;
          -  Patients with current severe, uncontrolled systemic disease (including, but not&#xD;
             limited to, clinically significant cardiovascular disease, pulmonary disease, or renal&#xD;
             disease, ongoing or active infection)&#xD;
&#xD;
          -  Patients with a history or complication of interstitial lung disease (ILD)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sponsor Chugai Pharmaceutical Co. Ltd</last_name>
    <role>Study Director</role>
    <affiliation>clinical-trials@chugai-pharm.co.jp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical trials information</last_name>
    <phone>only use Email</phone>
    <email>clinical-trials@chugai-pharm.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-Ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). For further details on Chugai's Data Sharing Policy and how to request access to related clinical study documents, see here (www.chugai-pharm.co.jp/english/profile/rd/ctds_request.html).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

